1. INTRODUCTION
===============

These are very interesting times in the field of gene regulation as it affects development and cancer. Since the late 1990s, the tenets of the "central dogma" have undergone revision as scientists began to appreciate that [rna]{.smallcaps}s, by themselves, play key regulatory roles.

Leading the charge in this revolution are the small (18--25 nucleotide) non-coding [rna]{.smallcaps}s called "small interfering" [rna]{.smallcaps}s (si[rna]{.smallcaps}s) and micro-[rna]{.smallcaps}s (mi[rna]{.smallcaps}s), which direct [rna]{.smallcaps} interference ([rna]{.smallcaps}i) phenomena. The si[rna]{.smallcaps}s and mi[rna]{.smallcaps}s are newly discovered regulatory molecules that control a variety of biologic processes, including development, metabolism, and aging [@b1-co16-4-61]--[@b3-co16-4-61]. The mi[rna]{.smallcaps}s often bind to complementary sequences in the 3′ untranslated regions of target messenger [rna]{.smallcaps}s (m[rna]{.smallcaps}s) to repress target gene expression; the si[rna]{.smallcaps}s can bind to any complementary sequence in a target m[rna]{.smallcaps}. Importantly, functional roles have been demonstrated for mi[rna]{.smallcaps}s in cancer [@b4-co16-4-61],[@b5-co16-4-61], and the potential exists to use similar molecules as cancer therapeutics.

The present review outlines the underlying rationales for considering small [rna]{.smallcaps} therapeutics. Although most of the attention has been given to the use of si[rna]{.smallcaps}s to inhibit gene function, we provide a broader overview and include novel and emerging strategies that are instead based on mi[rna]{.smallcaps}s. We highlight the potential of each strategy for cancer treatment and summarize the challenges that need to be overcome to fully harness [rna]{.smallcaps}i- and mi[rna]{.smallcaps}-based therapies.

2. THE MOLECULAR BASIS FOR siRNA- AND miRNA-MEDIATED SILENCING
==============================================================

The silencing mediated by [rna]{.smallcaps}i and mi[rna]{.smallcaps} is initiated when the double-stranded [rna]{.smallcaps} (ds[rna]{.smallcaps})--specific type [iii]{.smallcaps} endonuclease, Dicer, "recognizes" a ds[rna]{.smallcaps} substrate. Processing by Dicer and its accessory proteins yields 18- to 25-nucleotide heteroduplex small [rna]{.smallcaps}s (either si[rna]{.smallcaps}s or mi[rna]{.smallcaps}s, depending on their origin). The mi[rna]{.smallcaps}s are usually endogenously transcribed; the si[rna]{.smallcaps}s often derive from exogenous sources such as viruses [@b6-co16-4-61],[@b7-co16-4-61]. One of the strands of the small [rna]{.smallcaps} duplex is selected, loaded into Argonaute proteins, and assembled into an effector complex such as the [rna]{.smallcaps}-induced silencing complex ([risc]{.smallcaps}). The other strand is often cleaved or unwound and degraded [@b8-co16-4-61],[@b9-co16-4-61]. A key feature for the use of [rna]{.smallcaps}i in therapy is that the [risc]{.smallcaps} can be directly programmed by exogenous mature si[rna]{.smallcaps}s or mi[rna]{.smallcaps}s. In effect, this programming bypasses cleavage by Dicer and the interferon response triggered by ds[rna]{.smallcaps}s larger than 30 bp in mammalian cells [@b10-co16-4-61]. Generally, when a si[rna]{.smallcaps} fully pairs with a target m[rna]{.smallcaps}, the result is rapid and specific cleavage, an activity named "slicer" [@b11-co16-4-61].

In contrast to si[rna]{.smallcaps}s, mi[rna]{.smallcaps}s normally originate from gene-encoded precursor transcripts that are processed into precursor mi[rna]{.smallcaps}s. Those precursors fold as hairpins and serve as Dicer substrates [@b12-co16-4-61]. Embedded within the [risc]{.smallcaps}, mature mi[rna]{.smallcaps}s pair only partially with their m[rna]{.smallcaps} targets, thereby directing translation inhibition or reducing the stability of their target [@b13-co16-4-61].

The gene-targeting information is non-symmetrically encoded within mature si[rna]{.smallcaps}s or mi[rna]{.smallcaps}s. The 5′ portion of the mi[rna]{.smallcaps} at positions 2--7 is thought to encode the most important determinant to direct base-pairing with m[rna]{.smallcaps} targets. This portion (called the "core," "nucleus," or "seed" sequence) is most commonly conserved; it defines paralogous and orthologous families of mi[rna]{.smallcaps}s [@b14-co16-4-61]. Structural studies show a tight coordination of this 5′ determinant within the Argonaute proteins [@b15-co16-4-61]. The 3′ part of the mi[rna]{.smallcaps} or si[rna]{.smallcaps} is more amenable to chemical modifications, some of which occur naturally.

3. THE BIOLOGIC IMPLICATIONS OF miRNAS FOR CANCER
=================================================

To evaluate the potential of small [rna]{.smallcaps}s in cancer therapy, an appreciation of how extensively they are tied to the normal cell's gene regulation networks is essential. In human cells, mi[rna]{.smallcaps}s are estimated to account for more than 1000 genes (approximately 3% of the total estimated number of genes) and to exert direct negative regulative pressure on more than 30% of the entire coding gene set [@b14-co16-4-61],[@b16-co16-4-61]. Accordingly, mi[rna]{.smallcaps}s are known to regulate genes implicated in a wide range of cellular functions in development and homeostasis [@b17-co16-4-61]. In *Caenorhabditis elegans,* for example, the first two known mi[rna]{.smallcaps}s---*lin-4* and *let-7---*control timing of cell differentiation during development. In *let-7* mutants, stem cells in the skin frequently fail to terminally differentiate, electing instead to divide again. Such cellular events are the defining hallmarks of cancer [@b18-co16-4-61].

Because misregulation of genes that control cell proliferation and cell fate often contribute to cancer development, mi[rna]{.smallcaps}s are unsurprisingly also implicated in cancer biology. Early evidence in humans indicates that mi[rna]{.smallcaps} loci are associated with chromosome sites that are often deleted or amplified [@b19-co16-4-61], and whose expression is dramatically altered during the onset of cancer [@b20-co16-4-61]. Intense current research aims to precisely delineate the functions of mi[rna]{.smallcaps}s in transformation and tumour growth [@b21-co16-4-61]--[@b23-co16-4-61]. In an increasing number of reports, mi[rna]{.smallcaps}s are now being shown to be capable of acting as bona fide tumour suppressors or oncogenes, bringing about a major shift in the landscape of cancer research [@b24-co16-4-61].

4. siRNA- AND miRNA-BASED THERAPEUTIC STRATEGIES
================================================

The chemical properties of the various mi[rna]{.smallcaps}s vary little, and yet, through the sequences that they encode, they direct completely distinct activities. At least three distinct overall strategies were adopted early on for si[rna]{.smallcaps}- and mi[rna]{.smallcaps}-based therapies. Each one aims (reasonably) to exploit the sequence-directed properties of the small [rna]{.smallcaps}s:

-   First, *de novo* reprogramming of the [rna]{.smallcaps}i machinery can be utilized against a gene that has deleterious effects ([Figure 1](#f1-co16-4-61){ref-type="fig"}, panel 1).

-   Second, a physiologic mi [rna]{.smallcaps}--m[rna]{.smallcaps} pair could be reproduced by programming the [risc]{.smallcaps} using a known, beneficial mi[rna]{.smallcaps}---for example, a tumour suppressor mi[rna]{.smallcaps} ([Figure 1](#f1-co16-4-61){ref-type="fig"}, panel 2).

-   Third, a nonhydrolyzable mimic of an [rna]{.smallcaps} target could be generated to effectively sequester deleterious mi[rna]{.smallcaps}s from their pro-oncogenic functions ([Figure 1](#f1-co16-4-61){ref-type="fig"}, panel 3).

4.1 Harnessing RNAi: *De Novo* Programming with siRNAs
------------------------------------------------------

Perhaps the simplest and the most direct therapeutic strategy involving [rna]{.smallcaps}i is to harness and redirect its machinery against a detrimental m[rna]{.smallcaps} target. It therefore comes as no surprise that this strategy is by far the most advanced in clinical trials. The si[rna]{.smallcaps}-directed targeting of genes is currently being developed as a potential therapy in a great number of diseases [@b25-co16-4-61],[@b26-co16-4-61]. The keys to this strategy are identification of a functional and effective [rna]{.smallcaps}i target and optimization of the targeting process. The strategy can include, but is not limited to, knowing the uniqueness of the si[rna]{.smallcaps}'s target sequence in the genome, optimizing its loading into the [risc]{.smallcaps}, obtaining a measure of the accessibility of the si[rna]{.smallcaps} target site (structure, protein--[rna]{.smallcaps} interactions), and possibly even adding tolerated covalent modifications to the si[rna]{.smallcaps}. In addition, and common to each [rna]{.smallcaps}i- or mi[rna]{.smallcaps}-based therapy, is the need to deliver the [rna]{.smallcaps} molecule or analog to the correct tissue and m[rna]{.smallcaps} target (see the "Challenges" subsection).

Many si[rna]{.smallcaps}-based therapies are under development, but surprisingly few are directed at oncogenic targets. Among the cancer-directed approaches is the targeting of pleiotrophin, which effectively reduced tumour growth in mouse xenograft models of glioblastoma multiforme [@b27-co16-4-61]. Another initiative of interest is the successful targeting of the Ews--Fli1 fusion oncoprotein in mouse models of metastatic Ewing sarcoma [@b28-co16-4-61].

4.2 Tilting the Balance: miRNAs As Drugs
----------------------------------------

A second potential approach in [rna]{.smallcaps}i-based cancer therapy is to deliver a mature or engineered mi[rna]{.smallcaps} precursor to specific biologic compartments to affect its known and physiologic m[rna]{.smallcaps} targets. In effect, this strategy aims at the restoration, the strengthening, or the ectopic rewiring of known mi[rna]{.smallcaps}-target circuitry [@b29-co16-4-61],[@b30-co16-4-61]. In contrast with the *de novo* programming approach, this strategy relies heavily on prior and extensive characterization of the biologic functions of the mi[rna]{.smallcaps} of interest. The idea would be

-   to know the identity of the physiologic targets of the mi[rna]{.smallcaps} of interest, and

-   to have a good idea of how the associated genes are embedded within their genetic network.

This second aspect is important, considering that mi[rna]{.smallcaps}s often function as parts of loops (feedback and feed-forward) between gene networks. (For examples, see Li *et al.* [@b31-co16-4-61] and Xu *et al.* [@b32-co16-4-61])

One mi[rna]{.smallcaps} that fits each of these requirements is *let-7.* Overexpression of *let-7* in a mouse model of lung cancer involving an activated K*-ras* allele suppresses activating oncogenic *ras* mutations just as such overexpression does in *C. elegans* [@b33-co16-4-61],[@b34-co16-4-61]. Signalling by *ras* plays an important role in radioresistance, and radiotherapy is one of the three primary modalities used in combatting cancer. However, many cancers, including lung cancer, are radioresistant. Because *let-7* represses *ras, let-7* overexpression has been proposed to be a possible cause of radiosensitivity, a hypothesis that indeed proved to be the case in both lung cancer cells and in an *in vivo C. elegans* model [@b29-co16-4-61]. These data provided the first evidence that mi[rna]{.smallcaps}s could potentially augment current cancer therapies.

An even more recent publication reported the use of a similar strategy---named "mi[rna]{.smallcaps} replacement therapy"---aimed at restoring mi[r]{.smallcaps}26a expression in hepatocellular carcinoma. When delivered in a mouse model using adeno-associated virus, this mi[rna]{.smallcaps} was able to suppress proliferation and induce apoptosis, which resulted in inhibition of hepatocellular carcinoma progression [@b35-co16-4-61].

4.3 Sequence-Directed Inhibition: miRNAs As Drug Targets
--------------------------------------------------------

Where the strategies already discussed are based on programming of the [risc]{.smallcaps}, a third promising strategy involves inhibition of the endogenous functions of well-characterized mi[rna]{.smallcaps}s. This inhibition is accomplished by "base-pairing": using complementary nucleic acid analogs to block the unique signature of small [rna]{.smallcaps}s (mainly the "seed"). One major advantage of this strategy is that the constraints required to contact or base-pair with a mi[rna]{.smallcaps} sequence are likely to be much looser than the requirements to fit within the tightly coordinated binding pocket of the [risc]{.smallcaps} and to act as a functional [rna]{.smallcaps}i component. These looser constraints in turn allow for greater chemical and covalent modifications to be made to the backbone of the analog inhibitor to change its stability, mi[rna]{.smallcaps}-inhibiting properties, and even its pharmacokinetics and biodistribution. At this stage, the frontrunners of these modifications are the locked nucleic acids ([lna]{.smallcaps}s) [@b36-co16-4-61] 2′-*O-*methyl [@b37-co16-4-61],[@b38-co16-4-61] and 2′-*O*-methoxyethyl [@b39-co16-4-61],[@b40-co16-4-61]. In addition to combinations of these modifications, analogs such as the "antagomirs" (mi[r]{.smallcaps}s) are modified with phosphorothioate substitutions on the backbone and with cholesterol conjugation [@b36-co16-4-61].

A recent and successful example of this overall strategy is the *in vivo* inhibition of mi[r]{.smallcaps}122 mi[rna]{.smallcaps} using a 15-nucleotide [lna]{.smallcaps}-bearing analog [@b41-co16-4-61]. The liver-specific mi[r]{.smallcaps}122 has been implicated in cholesterol and lipid metabolism and has been linked to replication of hepatitis C virus ([hcv]{.smallcaps}) *in vitro* [@b42-co16-4-61]. A recent study by Elmen and colleagues is the first to report inhibition of mi[rna]{.smallcaps}s by analogs *in vivo* in nonhuman primates. Reduction of mature mi[r]{.smallcaps}122 levels in the liver was accompanied by a substantial and reversible reduction in plasma cholesterol, without inducing any detectable sign of toxicity or tissue damage [@b41-co16-4-61]. This work raised the possibility that mi[r]{.smallcaps}122 could be targeted in chronically infected [hcv]{.smallcaps} patients, for example, which could in turn reduce the associated risk of carcinoma. In a broader sense, this work highlights the potential of targeting mi[rna]{.smallcaps}s using [lna]{.smallcaps} analogs in therapy, with low toxicity and high specificity.

Although the use of mi[rna]{.smallcaps} inhibitors is only starting to emerge as a therapeutic strategy, an important number of studies have reported mi[rna]{.smallcaps} targeting by analogs in cell culture or mouse models. Successfully targeted and cancer-relevant mi[rna]{.smallcaps}s include mi[r]{.smallcaps}16; mi[r]{.smallcaps}21; mi[r]{.smallcaps}34a, b, and c; mi[r]{.smallcaps}29b; mi[r]{.smallcaps}221/222; and the 17 to approximately 92 cluster of mi[rna]{.smallcaps}s individually---and the list is rapidly growing (see Stenvang *et al.* [@b43-co16-4-61] and references therein). Considering the role of mi[rna]{.smallcaps}s in cancer, the low toxicity of [lna]{.smallcaps} in primates, and the feasibility of efficient targeting of mi[rna]{.smallcaps}s *in vivo,* the potential impact of this strategy is immense.

5. CHALLENGES
=============

By far the most important challenge faced by researchers developing therapeutic strategies based on [rna]{.smallcaps}i is the means to deliver the si[rna]{.smallcaps}s, mi[rna]{.smallcaps}s, or analogs to the correct cells in the organism. Intrinsically, [rna]{.smallcaps}s are polar and labile, and their pharmacokinetic properties are completely alien to most of the desired cellular destinations. The stability of the [rna]{.smallcaps} molecule can be greatly enhanced by blocking the 2′-hydroxy group of ribonucleotides and modifying the phosphodiester backbone, but delivery must be tailored and optimized for each tissue and cellular target. A few early reports describing direct delivery of naked, unmodified [rna]{.smallcaps} molecules to the target tissue appeared successful, one case being si[rna]{.smallcaps}s targeting respiratory syncytial virus to the lung [@b44-co16-4-61]. In addition, si[rna]{.smallcaps} targeting of vascular endothelial growth factors α and 1 in age-related macular degeneration has been reported [@b45-co16-4-61]. However, recent work by Kleinman *et al.* called the reasons for these findings into question when those authors reported that at least some of the anti-angiogenesis virtues of the si[rna]{.smallcaps} treatment were independent of its sequence [@b46-co16-4-61]. Instead, efficacy appeared to depend on the Toll-like receptor 3--triggered induction of the interferon γ response. That study was seen by some as a setback for si[rna]{.smallcaps}-based therapies. For others, it meant simply that [rna]{.smallcaps}i- or nucleic acid--based therapy in general requires additional fine-tuning to escape the innate immune response. Part of the solution is likely already underway, because an important variety of synthetic material has been established and successfully used for si[rna]{.smallcaps} or nucleic acid delivery. The efficient strategies reported range from direct conjugation of cholesterol and nucleic acids or analogs, to complexation or coating with liposomes or polycationic agents. (For a recent and thorough review on this topic, see Whitehead *et al.* [@b26-co16-4-61])

Another important concern for [rna]{.smallcaps}i and mi[rna-]{.smallcaps}based therapy is the unintentional targeting of m[rna]{.smallcaps}s, termed "off-targets." This effect has been well characterized using microarray studies of si[rna]{.smallcaps}-transfected cells, in which expression in an important number of genes declined with increased concentration of si[rna]{.smallcaps}s [@b47-co16-4-61],[@b48-co16-4-61]. It is also thought that ectopic expression of mi[rna]{.smallcaps}s can result in a related effect. Selective pressure normally disfavours the presence of sequences complementary to a mi[rna]{.smallcaps} "seed" in non-targets and co-expressed m[rna]{.smallcaps}s---a phenomenon termed "avoidance" [@b49-co16-4-61]. Ectopically expressed or overexpressed mi[rna]{.smallcaps}s in therapy can therefore potentially find sequences that are avoided under physiologic conditions.

In part, the delivery and off-target issues of si[rna]{.smallcaps}-and mi[rna]{.smallcaps}-based therapies are linked. Ideally, the means to deliver these nucleic acids, or their analogs, to cells would proceed so efficiently as to maintain low administered concentrations. More efficient delivery should reduce the number of cells exposed, favour uptake, and reduce the potential for off-target effects, hence maintaining a suitable therapeutic index.

6. CONCLUSIONS
==============

Although the field of [rna]{.smallcaps}i is still an emerging one, the benefits of understanding the roles of mi[rna]{.smallcaps}s and si[rna]{.smallcaps}s in cancer are potentially enormous, not only for their roles as cancer loci, but also because for the growing likelihood that small [rna]{.smallcaps}s can be used as therapeutics in treating cancer itself [@b30-co16-4-61].
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